2067.5000 25.10 (1.23%)
NSE Sep 18, 2025 11:52 AM
Volume: 483.3K
 

2067.50
1.23%
HDFC Securities
Maintain BUY with a revised TP of Rs 1,000 (18x Sep-19E and Rs 135/sh for innovative pipeline). Glenmarks (GNP) 2QFY18 performance was slightly below expectations. The overall top-line grew 2% YoY to Rs 22.2bn. While a sequential decline in the US was expected on account of the loss of exclusivity of gZetia, US$113mn for the quarter was below our expectations. The EBITDA margin came in at 16%. There were one-time bonuses of Rs 1.1bn paid during the quarter, adjusted for which the margin would have been 21% and ~100bps ahead of our estimates. PAT was ~Rs 2bn, down ~9% YoY.
Glenmark Pharmaceuticals Ltd. has gained 25.06% in the last 3 Months
More from Glenmark Pharmaceuticals Ltd.
Recommended